natgillin/translations-raw huggingface dataset:
Myopathy, back pain
miopatija, bolečina v hrbtu,
Myopathy, back pain
miopatija, bolečine v hrbtu
Myopathy, back pain, musculoskeletal pain, myalgia
miopatija, bolečina v hrbtu, bolečina v mišicah in kosteh, mialgija
Myopathy, back pain, musculoskeletal pain, myalgia
miopatija, bolečine v hrbtu, bolečine v mišicah in kosteh, mialgija
Myopathy, back pain, musculoskeletal pain, myalgia
miopatija, bolečine v hrbtu, mišičnoskeletne bolečine, mialgija
Myopathy/myositis, arthralgia, myalgia, pain in the extremities, back pain, muscle spasm, neck pain, flank pain
miopatija/miozitis, artralgija, mialgija, bolečine v okončinah, bolečine v hrbtu, mišični krči, bolečine v vratu, ledvene bolečine
Myopia,
astenopija,
Myopia,
miopija,
Myopia, Asthenopia,
miopija,
myositis (myalgia, myopathy, polymyalgia rheumatica and rhabdomyolysis)
miozitis (mialgija, miopatija, revmatična polimialgija in rabdomioliza)
Myositis, blood creatine phosphokinase increased
miozitis, zvišanje kreatin-fosfokinaze v krvi
Myositis, increased myoglobin, muscular weakness,
miozitis, zvišana vrednost mioglobina, mišična
myositis, rhabdomyolysis, increased CPK, osteonecrosis (see section 4.4), periarthritis.
miozitis, rabdomioliza, povišan CPK, osteonekroza (glejte poglavje 4.4), periartritis
Myositis, rhabdomyolysis, myalgia, myopathy/CPK increased
miozitis, rabdomioliza, mialgija, miopatija/zvišana CPK
myositisp, musculoskeletal painq, pain in extremity, arthritisr
miozitisp, mišično-skeletna bolečinaq, bolečine v okončini, artritisr
Myozyme 50 mg powder for concentrate for solution for infusion
Myozyme 50 mg prašek za koncentrat za raztopino za infundiranje
Myozyme contains an artificial enzyme called alglucosidase alfa – this can replace the natural enzyme which is lacking in Pompe disease.
Zdravilo Myozyme vsebuje umetni encim, ki se imenuje alglukozidaza alfa – nadomesti lahko naravni encim, ki ga primanjkuje pri Pompejevi bolezni.
Myozyme contains sodium
Zdravilo Myozyme vsebuje natrij
Myozyme is indicated for long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid -glucosidase deficiency).
Zdravilo Myozyme je namenjeno dolgoročni encimski nadomestni terapiji (ERT - enzyme replacement therapy) pri bolnikih s potrjeno diagnozo Pompejeve bolezni (pomanjkanje - glukozidaze).
Myozyme should be administered as an intravenous infusion.
Zdravilo Myozyme morate dati z intravensko infuzijo.
Mysimba 8 mg/90 mg prolonged-release tablets
Mysimba 8 mg/90 mg tablete s podaljšanim sproščanjem
Mysimba contains lactose (a type of sugar)
Zdravilo Mysimba vsebuje laktozo (vrsto sladkorja)
Mysimba has been shown to cause fits (seizures) in up to 1 in 1,000 patients (see also section 4).
Pokazalo se je, da zdravilo Mysimba povzroča krče (epileptične napade) pri največ 1 od 1.000 bolnikov (glejte tudi poglavje 4).
Mysimba is approved for use in patients with an initial body mass index of 30 or greater; it can also be given to those with a body mass index between 27 and 30 if they have additional weight-related conditions such as controlled high blood pressure (hypertension), type 2 diabetes or high levels of lipid (fat) in the blood.
Zdravilo Mysimba je odobreno za uporabo pri bolnikih z izhodiščnim indeksom telesne mase, ki znaša 30 ali več; uporabiti ga je mogoče tudi pri tistih, ki imajo indeks telesne mase med 27 in 30, če imajo dodatna obolenja, povezana s telesno maso, kot so nadzorovan visok krvni tlak (hipertenzija), sladkorna bolezen tipa 2 ali visoke ravni lipidov (maščob) v krvi.
Mysimba is available in packs containing 112 tablets.
Zdravilo Mysimba je na voljo v pakiranjih, ki vsebujejo po 112 tablet.
Mysimba is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of
Zdravilo Mysimba je kot dodatek k dieti z zmanjšano vsebnostjo kalorij in povečani telesni dejavnosti indicirano za uravnavanje telesne mase pri odraslih bolnikih (≥18 let) z izhodiščnim indeksom telesne mase (ITM):
Mysimba might make you feel dizzy which may weaken your ability to concentrate and react.
Zdravilo Mysimba lahko povzroči občutek omotičnosti, ki oslabi vašo sposobnost koncentracije in reagiranja.
Mysimba must not be used in certain patients at particular risk of side effects, including patients with severely reduced kidney or liver function, those with high blood pressure that is not under control, those who have ever had seizures (fits), certain psychological problems or who have a brain tumour or are undergoing withdrawal from alcohol or certain drugs.
Zdravilo Mysimba se ne sme uporabljati pri določenih bolnikih s posebnim tveganjem za neželene učinke, kot so bolniki z močno zmanjšanim delovanjem ledvic ali jeter, bolniki z visokim krvnim tlakom, ki ni pod nadzorom, bolniki, ki so kdaj imeli epileptične napade (krče) ali določene psihološke težave, in bolniki, ki imajo možganski tumor ali se trenutno odvajajo alkohola ali določenih drog.
Mysimba prolonged-release tablets are blue, biconvex, round tablets debossed with “NB-890” on one side.
Tablete zdravila Mysimba s podaljšanim sproščanjem so modre okrogle bikonveksne tablete, ki imajo na eni strani vtisnjeno oznako "NB-890".
Mysimba™ 8 mg/90 mg prolonged-release tablets naltrexone hydrochloride / bupropion hydrochloride
Mysimba™ 8 mg/90 mg tablete s podaljšanim sproščanjem naltreksonijev klorid/bupropionijev klorid
Mínutes From Initial Surgical Incision
Minute, pretekle od prvega kirurškega reza
N $ (cases/controls)
N $ (primeri/kontrole)
n (% of patients)
n (% bolnikov)
n (%)
n = 2.635 n (%)
n (%)
n = 2.689 n (%)
n (%) (95% CI)
n (%) (95 % IZ)
N (%) of Recurrent Joints in Each Intervalb
N (%) sklepov s ponovitvij o za vsak intervalb
n (%/yr)a
n (%/leto)a
N (events/patients) (%)
N (dogodki/bolnice) (%)
n (ITT population)
n (populacija ITT)
n (ITT population)
Populacija ITT
n / N
n/N
N 10,054
N 10.054
N 10,200
N 10.200
N 10,273
N 10.273
N 11,798
N 11.798
N 11,799
N 11.799
n = 1,501
n = 1.501
n = 1,508
n = 1.508
N = 100 N = 99
N=100 N=99
N = 101
N=101
n = 106
(13,4-24,6)
n = 128
(10,2-17,4)
N = 128†
30,0
n = 129
90,7 (12,22)
N = 129†
30,8
N = 13
n =13
n = 131
n = 129
N = 131†
0,32
N = 1521
N = 1.521
N = 153
PASI 100
N = 1533
N = 1.533
N = 1534
N = 1.534
N = 154
26 (6,5)
N = 17
n=17
N = 170
0,61 [0,44; 0,84]
N = 170
0,89 [0,62; 1,28]
n = 177
Cis+5-FU n = 177
N = 2,044
N = 2.044
n = 2,659
n = 2.659
n = 2,673
n = 2.673
N = 2,780 n (%/year)
n = 2.689 n (%)
N = 2,791 n (%/year)
n = 2.635 n (%)
N = 2455-2696
N = 2455–2696
N = 29
80,0
n = 30
90,1 (11,66)
N = 31
(36,6; 65,2)
N = 319-609
N = 319–609
N = 32
n=32
N = 34 N = 38
N=34 N=38
N = 377-591
N = 377–591
N = 39 N = 38
N=39 N=38
n = 4 for genotype 2 and n = 2 for genotype 4 n = 4 for genotype 2, n = 2 for genotype 4 and n = 1 for genotype 6.
n = 4 za genotip 2 in n = 2 za genotip 4 n = 4 za genotip 2, n = 2 za genotip 4 in n = 1 za genotip 6
n = 4 for genotype 2 and n = 4 for genotype 4
n = 4 za genotip 2 in n = 4 za genotip 4
N = 439-551
N = 439–551
N = 498-550
N = 498–550
N = 51
51,0
N = 599
N=599
N = 604
N=604
N = 84
Odziva, n (%)
N = number of patients
N = število bolnikov
N = number of subjects
N = število preiskovancev
N = number of subjects included in each group (1) TVC naïve: includes all vaccinated subjects (who received at least one dose of vaccine) who had normal cytology, were HPV DNA negative for 14 oncogenic HPV types and seronegative for HPV-16 and HPV-18 at baseline.
N = število oseb, vključenih v vsako skupino (1) Naivna TVC: vključuje vse cepljene preiskovanke (ki so dobile vsaj en odmerek cepiva), ki so imele normalno citologijo, so bile HPV-DNA-negativne za 14 onkogenih tipov HPV in seronegativne za HPV-16 in HPV-18 ob izhodišču.
N = number of subjects included in each group (1) TVC naïve: includes all vaccinated subjects (who received at least one dose of vaccine) who had normal cytology, were HPV DNA negative for 14 oncogenic HPV types and seronegative for HPV-16 and HPV-18 at baseline.
N = število oseb, vključenih v vsako skupino (1)Naivna TVC: vključuje vse cepljene preiskovanke (ki so dobile vsaj en odmerek cepiva), ki so imele normalno citologijo, so bile HPV-DNA-negativne za 14 onkogenih tipov HPV in seronegativne za HPV-16 in HPV-18 ob izhodišču.
N = number of subjects included in each group n = number of cases (1) ATP: includes women who received 3 doses of vaccine, were DNA negative and seronegative at month 0 and DNA negative at month 6 to the relevant HPV type (HPV- 16 or HPV-18) (2) mean follow-up of 40 months post dose 3
N = število oseb, vključenih v vsako skupino n = število primerov (1) PP: vključuje ženske, ki so prejele 3 odmerke cepiva ter so bile ob mesecu 0 DNA-negativne in seronegativne ter ob mesecu 6 DNA-negativne za zadevni tip HPV (HPV-16 ali HPV-18) (2) povprečno spremljanje 40 mesecev po 3. odmerku
N = number of subjects included in each group n = number of cases (1) ATP: includes women who received 3 doses of vaccine, were DNA negative and seronegative at month 0 and DNA negative at month 6 to the relevant HPV type (HPV-16 or HPV-18) (2) including 4 cases of CIN2+ and 2 cases of CIN3+ in which another oncogenic HPV type was identified in the lesion, concomitantly with HPV-16 or HPV-18.
N = število oseb, vključenih v vsako skupino n = število primerov (1) PP: vključuje ženske, ki so prejele 3 odmerke cepiva ter so bile ob mesecu 0 DNA-negativne in seronegativne ter ob mesecu 6 DNA-negativne za zadevni tip HPV (HPV-16 ali HPV-18) (2) vključno s 4 primeri CIN2+ in 2 primeroma CIN3+, pri katerih so v spremembi hkrati s HPV-16 ali HPV- 18 ugotovili še nek drug onkogeni tip HPV.
N = number of subjects included in each group n = number of cases (1) TVC: includes all vaccinated subjects (who received at least one dose of vaccine) irrespective of HPV DNA status, cytology and serostatus at baseline.
N = število oseb, vključenih v vsako skupino n = število primerov (1) TVC: vključuje vse cepljene preiskovanke (ki so prejele vsaj en odmerek cepiva), ne glede na njihovo izhodiščno stanje HPV-DNA, izhodiščno citologijo ali izhodiščno serološko stanje.
N = number of subjects ND = not determined
n = število preiskovancev ND = ni določeno
N = Number of subjects randomised
N = število randomiziranih preiskovancev
n = number of subjects with SVR12 response; N = total number of subjects per group.
n = število oseb z odzivom SVR12; N = skupno število oseb v skupini.
n = number of subjects with the event; N = total number of subjects a Per embryo transfer.
n = število preiskovank z dogodkom; N = celotno število preiskovank a na prenos zarodka
n = randomised patients who received at least 1 dose of study medication
n = število randomiziranih bolnikov, ki so prejeli vsaj 1 odmerek preiskovanega zdravila
n = total number of patients per treatment group.
n = skupno število bolnikov v skupini zdravljenja.
N = total number of patients treated.
N = celotno število zdravljenih bolnikov.
N events/patients (%)
N dogodkov/bolnice (%)
N is number of subjects per model estimate. p-values for lurasidone vs. placebo were adjusted for multiple comparisons.
N je število oseb na model ocene. p-vrednosti za lurasidon v primerjavi s placebom so bile prilagojene za multiple primerjave.
N is the number of randomized subjects with at least one dose of double-blind medicine during short-term double-blind treatment. n = number of subjects with non-missing baseline and a Week 24 value.
N je število randomiziranih bolnikov, ki so prejeli vsaj en odmerek dvojno slepo dodeljenega zdravila med kratkotrajnim dvojno slepim zdravljenjem. n = število bolnikov, ki niso imeli manjkajoče vrednosti izhodiščno in po 24 tednih.
n median (range)
n mediana (razpon)
n n
Ščitnik
N Number of patients evaluable for quality of life analyses
a Prikazane so vrednosti za zdravilo IRESSA v primerjavi s karboplatinom/paklitakselom N Število bolnikov, primernih za analize kakovosti življenja
N Number of patients randomised
N število randomiziranih bolnikov.
n of subjects
Število oseb (n)
N pregnancies
Št. nosečnosti
N randomised
N randomiziranih bolnikov
n reflects randomised and treated patients
a n pomeni randomizirane bolnike
n reflects randomised and treated patients
n pomeni randomizirane in zdravljene bolnike
N total
Skupno št.
n, sudden death (see section 4.4)11
, nenadna smrt (glejte poglavje 4.4)11
n, sudden death (see section 4.4)11
nenadna smrt (glejte poglavje 4.4) 11
n, sudden death (see section 4.4)11
Prekatna tahikardija/fibrilacij a, nenadna smrt (glejte poglavje 4.4)11
N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoly-sn-glycero-3-phosphoethanolam ine (MPEG-2000-DSPE); Sucrose octasulphate; 2- [4- (2-Hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES buffer); sodium chloride and water for injections.
N-(karbonil-metoksipolietilenglikol-2000)-1,2-distearoil-sn-glicero-3-fosfoetanolamin (MPEG-2000-DSPE); saharozni oktasulfat; 2- [4- (2-hidroksietil)piperazin-1-il]etansulfonska kislina (pufer HEPES); natrijev klorid in voda za injekcije.
N-acetyl-l cysteine
N-acetil-l cistein
N-acetylgalactosamine 4-sulfatase, which breaks down specific substances (glycosaminoglycans) in the body.
N-acetilgalaktozamin 4-sulfataza, ki razgrajuje določene snovi (glikozaminoglikane) v telesu.
N-dealkylation, O-demethylation, oxidation and partial loss of the PEG chain.
O-demetilacijo, oksidacijo in delno izgubo verige PEG.
N-dealkylbuprenorphine is a -opioid agonist with weak intrinsic activity.
N-dealkilbuprenorfin je agonist -opioidnih receptorjev s šibkim intrinzičnim delovanjem.
N-demethylation, catalysed by CYP1A1, CYP3A4, CYP2C8 and CYP2J2 is the major biotransformation pathway of riociguat leading to its major circulating active metabolite M-1 (pharmacological activity: 1/10th to 1/3rd of riociguat) which is further metabolised to the pharmacologically inactive N-glucuronide.
N-demetilacija, ki jo katalizirajo CYP1A1, CYP3A4, CYP2C8 in CYP2J2, je glavna pot biotransformacije riociguata, ki privede do nastanka glavnega aktivnega presnovka M-1 v krvnem obtoku (farmakološka aktivnost: 1/10 do 1/3 aktivnosti riociguata) in nadalje do farmakološko neaktivnega N-glukuronida.
N-Desethylbrinzolamide accumulated in RBCs to steady state within 20-28 weeks reaching concentrations ranging from 6-30 µM. The inhibition of total RBC CA activity at steady state was approximately 70-75%.
N-desetilbrinzolamid se je nakopičil v eritrocitih in dosegel v njih stanje dinamičnega ravnovesja v 20 do 28 tednih, pri koncentraciji od 6 do 30 µM. Inhibicija celotne aktivnosti eritrocitne CA v stanju dinamičnega ravnovesja je bila približno od 70 do 75%.
N-desethylbrinzolamide do not inhibit cytochrome P450 isozymes at concentrations at least 100-fold above maximum systemic levels.
N-desetilbrinzolamid ne zavirata izoencimov citokroma P450 pri koncentracijah, ki predstavljajo najmanj 100-kratnik največjih sistemskih vrednosti.
N-desmethyl enzalutamide was not metabolized by CYPs in vitro.
N-desmetil enzalutamid se in vitro ni presnovil z encimi skupine CYP.
N-desmethyl metabolite contributed a mean of less than 7 % (range 4-9 %) of the total medicinal product related material accounted for in the urine and faeces.
Presnovek N-desmetil predstavlja v povprečju manj kot 7 % (razpon 4-9 %) skupnih z zdravilom povezanih snovi prisotnih v urinu in blatu.
N-desmethyl metabolite) is 96 % bound to plasma proteins, this results in the mean maximum free plasma concentration for sildenafil of 18 ng/mL (38 nM).
N-desmetilni presnovek) 96 % vezan na beljakovine v plazmi, je srednja največja koncentracija prostega sildenafila v plazmi 18 ng/ml (38 nM).
N-desmethyl metabolite) is 96% bound to plasma proteins, this results in the mean maximum free plasma concentration for sildenafil of 18 ng/mL (38 nM).
N-desmetilni presnovek) 96 % vezan na beljakovine v plazmi, je srednja največja koncentracija prostega sildenafila v plazmi 18 ng/ml (38 nM).
N-desmethyl-sildenafil
N-demetil-sildenafil
N-desmethyl-vandetanib is primarily produced by CYP3A4, and vandetanib-N-oxide by flavin-containing monooxygenase enzymes (FM01 and FMO3).
N-desmetil-vandetanib nastane predvsem z delovanjem CYP3A4, vandetanib-N-oksid pa z delovanjem flavin vsebujočih monooksigenaznih encimov (FMO1 in FMO3).
N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose.
Na računa N-metiliranega derivata pregabalina, ki je glavni presnovek pregabalina v urinu, je šlo 0,9 % odmerka.
N-methylnicotinamide (MNA) and to N-methyl-2-pyridone-5-carboxamide (2PY).
N-metil-2-piridon-5-karboksamid (2PY).
N-Methylpyrrolidone Water for injection
N-metilpirolidon Voda za injekcije
N-monodesmethyl diltiazem: AUC: 0 37% (0 17 to 0 52)
AUC: ↓ 37 % (↓ 17 do ↓ 52)
N. gonorrhoeae IE (insufficient evidence)
N. gonorrhoeae ni dovolj podatkov
n.a.
NP
n.a. = not available
NP = ni podatkov
N.E.
NO
N.S.
ni znač.
N.V. Organon, Kloosterstraat 6, Postbus 20, 5340 BH Oss,
N.V. Organon Kloosterstraat 6 Postbus 20 5340 BH Oss
n/a
(n=237)
n/a
22/21
N/A
37,0
N/A
N/A 29,3
N/A
n/v
N/A
np
N/A
zatilje
N/A (Cats)
Izmišljeno ime
N/A (Sheep)
gumijasto
n/a 0.0072
ni podatka
n/a 0.0072
ni podatka 0,0072
N/A = not applicable
N/A = navedba smiselno ni potrebna
N/A = “Not applicable”, there were no responders therefore 95% CI is not applicable
N/A = “navedba smiselno ni potrebna: v tej skupini ni bilo nobenega bolnika z odzivom, zato navedba 95% IZ ni smiselna
N/A N/A
22,1 (14,6; N/E)
N/A N/A
5,1 (64,2;83,1)
N/A N/A
NA NA
N/A: Not Applicable
N/A: Navedba smiselno ni potrebna.
N/Ac 31.5 (28.9,
n = 118
N/Ac N/R
48,0)
n/N % 95% CI n/N % 95% CI
n/N % 95 % IZ n/N % 95 % IZ
N/R
94,3)
N355K
A352P
N: number of patients enrolled
N: število vključenih bolnikov
N: number of patients in a treatment group.
N: število bolnikov v zdravljeni skupini.
n: response-evaluable patients
n: odgovor preiskovanih bolnikov
n: response-evaluable patients
n: odziv preiskovanih bolnikov
N= 16
n=16
N= 17
n=17
N= 201
n = 201
N= 238
n = 238
n= 259 n= 260
n = 259
N= 298
n = 298
N= 330
n = 330
N= 68
n = 68
N= 71
n = 71
N= 73
n = 73
N= 75
n = 75
N= 77
n = 77
N= 79
n = 79
N= 80
n = 80
n= number of cases (1) ATP: includes women who received 3 doses of vaccine, were DNA negative at month 0 and at month 6 to the relevant HPV type.
n = število primerov (1) PP: vključuje ženske, ki so dobile 3 odmerke cepiva ter so bile ob mesecih 0 in 6 DNA-negativne za zadevni tip HPV.
n= number of cases (1) ATP: includes women who received 3 doses of vaccine, were DNA negative at month 0 and at month 6 to the relevant HPV type.
n = število primerov (1)PP: vključuje ženske, ki so dobile 3 odmerke cepiva ter so bile ob mesecih 0 in 6 DNA-negativne za zadevni tip HPV.
N= Number of individuals randomized to the respective vaccination group who received at least one injection. n= Number of individuals contributing to the analysis.
N = število oseb, randomiziranih v skupino s posameznim cepivom, ki so prejele vsaj eno injekcijo n = število oseb, vključenih v analizo
N= number of subject in each group n= number of subjects reporting at least one event in each group 6M PI = 6-month persistent infection
N = število preiskovank v posamezni skupini n = število preiskovank, ki so navedle vsaj en dogodek, v posamezni skupini 6-mesečna p. o. = 6-mesečna persistentna okužba
N=1
N = 1
N=1 [95% CI]
[27,8;
N=1,718
N = 1.718
n=1,724 35 (2.34%)
35 (2,34 %)
n=1,741 59 (4.07%)
59 (4,07 %)
n=1,970 4.4%
n=1.970 4,4
n=1,970 7.4%
n=1.970 7,4
n=10 for AUC12h excluding Cmin value below LLOQ, n=10 for reference
n=10 za AUC12h brez vrednosti Cmin pod LLOQ, n=10 za referenco
N=100 61% (51-71)
61 % (51-71)
N=100 98% (93-100)
98 % (93-100)
N=1006 n (%)
n = 1.006 n (%)
N=103 c
n = 103 c
N=106
9,2 (8,1-10,6)
N=106
j et
n=106 11.7
n = 128
N=1149 100% (99-100)
N=1149 100 % (99-100)
N=1152 100% (99-100)
N=1152 100 % (99-100)
N=1152 84% (82-86)
N=1152 84 % (82-86)
N=12 NR (5.0, NR)
ND (5,0, ND)
N=123 to 220†
N = 123 do 220
N=123 to 220†
N =123 do 220
N=124
n = 124
n=126
n = 126
N=127 (ITT
n = 127 (ITT populacija)
N=127 (ITT
n=127 (ITT
N=127 (ITT
n=127 (ITT populacija)
N=128
N = 128
n=128 15.7
36,7
N=13
N=71
N=130 (ITT
n=130 (ITT
N=138
n = 138
N=139
n = 139
N=14
odmerku n=14
N=141
n = 141
n=145
72,6
N=145
n = 145
N=147
n = 147
N=148
N=194
N=149
Placebo N=149
N=15
N=21
N=157
n = 157
N=163
17 (4,3)
N=163 45 (27.6%)
PGA: čisto/minimalno
N=17 25.0 (7.8,47.2)
transformacija v pospešeno/blastno fazof
N=170
n = 170
N=172
n = 172
n=173
n = 173
n=176
mikro gramov
n=176
mikro- gramov
N=177 to 396‡
N = 177 do 396
N=178††
N = 178
N=1817
n = 1817
N=1823
n = 1823
N=194
(2,56-3,58)
N=196 (1 study)
N = 196 (1 študija)
N=2,413
N = 2.413
N=2,609
(n = 840)
N=2,635
enoksaparin/ varfarin
N=2,689
enoksaparin/ varfarin
n=2,744 9.3%
n=2.744 9,3
n=2,748 5.6%
n=2.748 5,6
n=2,852 10.4%
n=2.852 10,4
n=2,852 12.1%
n=2.852 12,1
n=2,852 8.1%
n=2.852 8,1
n=2,852 9.3%
n=2.852 9,3
N=20 4.6 (4.6, 6.5)
4,6 (4,6, 6,5)
N=203 c
n = 203 c
N=204†
N = 204
N=209
n = 209
N=21
26.teden
N=223 (1 study)
N = 223 (1 študija)
N=229
0.0
N=237
n = 237
N=240 (ITT
n=240 (ITT
N=240 (ITT population)
n = 240 (ITT populacija)
N=240 (ITT population)
n=240 (ITT populacija)
N=242 (ITT
n=242 (ITT
N=242 (ITT population)
n = 242 (ITT populacija)
N=242 (ITT population)
n=242 (ITT populacija)
N=244
j et
N=244 84.6 (79.0,
72,1 (65,2;
N=246
n = 246
N=248
n = 248
N=249**
N = 249
N=26
152 (123,
n=268
5,7 (4,2-7,3)
N=274
n = 274
N=277
n = 277
N=28
odmerku n=28
N=291 36% (31-42%)
36 % (31-42 %)
n=292
mikro gramov
n=292
mikro- gramov
N=3 [95% CI]
45,6]
N=322††
N = 322
n=331
0,00043
n=337
p-vrednostc
n=345
n = 345
N=37
negativni
N=40
negativni
N=411
9,2 (8,1–10,6)
N=42
n = 42
N=421 100% (99-100)
100 % (99-100)
N=422 100% (99-100)
100 % (99-100)
N=426 22% (18-26)
22 % (18-26)
N=426 82% (78-85)
82 % (78-85)
N=47
90,6 (14,01)
N=472
n = 472
N=48
91,6 (12,54)
N=49
45,6
N=5 [95% CI]
[95 % IZ]
N=530 (4 studies)
N = 530 (4 študije)
N=532 (3 studies)
N = 532 (3 študije)
N=537
n = 537
N=54
90,6 (12,13)
N=542
n = 542
N=545
n = 545
N=551
n = 551
N=554
n = 554
N=558
n = 558
N=593
n = 593
N=594
n = 594
N=60
vanci
N=60 28.3 (17.5,41.4)
84,0 (75,8; 89,6)
N=606
n = 606
N=607
n = 607
N=64 14.4 (6.0,26.4)
22,1 (14,6; N/E)
N=65 n (%), p value
40 mg N=65 n (%), vrednost p
N=65 n (%), p value
n (%), vrednost p
N=66 for the NS5B target.
N = 66 za tarčni gen NS5B.
N=69
96,8 (94,0;
N=71
SRH
N=719
n = 719
N=723
n = 723
n=73
76,7
N=82 12.7 (10.2, 14.3)
(meseci)
N=84
77,8)
n=84
n = 84
N=934 to 1270‡
N = 934 do 1270
N=989 n (%)
n = 989 n (%)
N=990 n (%)
n = 990 n (%)
N=999 n (%)
n = 999 n (%)
N=number in Intent-to-treat population mcg = micrograms n/e = not evaluated
N = število v populaciji z-namenom-zdravljenja mcg = mikrogrami n/o = ni ocenjeno
N=Number of individuals randomized to the respective vaccination group who received at least one injection. n=Number of individuals contributing to the analysis.
N = število oseb, randomiziranih v skupino s posameznim cepivom, ki so prejele vsaj eno injekcijo n = število oseb, vključenih v analizo
N=Number of individuals with at least 1 follow-up visit after Month 7.
N = število oseb, ki so imele vsaj 1 kontrolni obisk po 7. mesecu.
NA
0,47
NA
0,60
NA
0,71
NA
1,12
NA
5,14
NA
n.r.
NA
n.s.
NA
n/r
NA
n/v
NA
Večja
NA (NA to NA)
NP (NP-NP)
NA = not applicable
NA = ne velja za ta primer
NA = Not Applicable a BMD Z-scores not adjusted for height and weight b Primary safety endpoint through week 72
a Z-indeks MGK ni prilagojen za telesno višino in maso b Primarni varnostni izid v 72. tednu
NA = Not available
NA = podatkov ni na voljo
NA = not available/not applicable
n/n = podatkov ni na voljo/navedba ni smiselna/potrebna
NA NA
8,6
NA Not applicable
NA ne velja za ta primer
NA Not Applicable
NA ne velja za ta primer.
NA Not Applicable
NP Ne pride v poštev
NA §
NP §
NA †
NP
NA***
n/s
NA-Not Applicable
NA ne velja za ta primer.
NA: Not available $ The number of fully vaccinated (2 doses) and unvaccinated cases and controls is given.
NP: ni podatka $ Navedeno je število v celoti cepljenih (2 odmerka) in necepljenih primerov in kontrol.
NA= not applicable
NA = ni na voljo.
NA= not available
np = ni podatka